Janssen Research & Development, LLC , 1400 McKean Road , Spring House , Pennsylvania 19477 , United States.
ImmunoGen, Inc. , 830 Winter Street , Waltham , Massachusetts 02451 , United States.
Anal Chem. 2018 Apr 17;90(8):5314-5321. doi: 10.1021/acs.analchem.8b00411. Epub 2018 Apr 3.
Bioanalysis of antibody-drug conjugates (ADCs) is challenging due to the complex, heterogeneous nature of their structures and their complicated catabolism. To fully describe the pharmacokinetics (PK) of an ADC, several analytes are commonly quantified, including total antibody, conjugate, and payload. Among them, conjugate is the most challenging to measure, because it requires detection of both small and large molecules as one entity. Existing approaches to quantify the conjugated species of ADCs involve a ligand binding assay (LBA) for conjugated antibody or hybrid LBA/liquid chromatography/tandem mass spectrometry (LC/MS/MS) for quantitation of conjugated drug. In our current work for a protein-drug conjugate (PDC) using the Centyrin scaffold, a similar concept to ADCs but with smaller protein size, an alternative method to quantify the conjugate by using a surrogate peptide approach, was utilized. The His-tagged proteins were isolated from biological samples using immobilized metal affinity chromatography (IMAC), followed by trypsin digestion. The tryptic peptide containing the linker attached to the payload was used as a surrogate of the conjugate and monitored by LC/MS/MS analysis. During method development and its application, we found that hydrolysis of the succinimide ring of the linker was ubiquitous, taking place at many stages during the lifetime of the PDC including in the initial drug product, in vivo in circulation in the animals, and ex vivo during the trypsin digestion step of the sample preparation. We have shown that hydrolysis during trypsin digestion is concentration-independent and consistent during the work flow-therefore, having no impact on assay performance. However, for samples that have undergone extensive hydrolysis prior to trypsin digestion, significant bias could be introduced if only the non-hydrolyzed form is considered in the quantitation. Therefore, it is important to incorporate succinimide hydrolysis products in the quantitation method in order to provide an accurate estimation of the total conjugate level. More importantly, the LC/MS/MS-based method described here provides a useful tool to quantitatively evaluate succinimide hydrolysis of ADCs in vivo, which has been previously reported to have significant impact on their stability, exposure, and efficacy.
抗体药物偶联物 (ADC) 的生物分析具有挑战性,这是由于其结构的复杂、异质性以及复杂的代谢分解。为了全面描述 ADC 的药代动力学 (PK),通常会定量分析几种分析物,包括总抗体、缀合物和有效载荷。在这些分析物中,缀合物是最难测量的,因为它需要同时检测小分子和大分子作为一个实体。现有的定量 ADC 缀合物种的方法包括用于缀合抗体的配体结合分析 (LBA) 或用于定量缀合药物的混合 LBA/液相色谱/串联质谱 (LC/MS/MS)。在我们当前使用 Centyrin 支架的蛋白药物偶联物 (PDC) 的工作中,我们使用了一种替代方法,通过使用替代肽方法来定量缀合物。该方法使用固定化金属亲和色谱 (IMAC) 从生物样本中分离 His 标记的蛋白,然后进行胰蛋白酶消化。将与有效载荷相连的接头的肽用作缀合物的替代物,并通过 LC/MS/MS 分析进行监测。在方法开发及其应用过程中,我们发现接头的琥珀酰亚胺环的水解普遍存在,在 PDC 的整个生命周期中都在发生,包括在初始药物产品中、在动物体内循环中以及在样品制备的胰蛋白酶消化步骤的离体过程中。我们已经证明,在胰蛋白酶消化过程中的水解是与浓度无关的,并且在整个工作流程中是一致的 - 因此,不会对测定性能产生影响。然而,如果仅考虑未水解的形式进行定量,对于在胰蛋白酶消化之前已经经历广泛水解的样品,可能会引入显著的偏差。因此,在定量方法中纳入琥珀酰亚胺水解产物对于提供总缀合物水平的准确估计非常重要。更重要的是,这里描述的基于 LC/MS/MS 的方法提供了一种有用的工具,可用于定量评估体内 ADC 的琥珀酰亚胺水解,这已被报道对其稳定性、暴露和疗效有重大影响。